Abstract
Liquid biopsy has already entered clinical practice in non-small cell lung carcinoma (NSCLC) patient care by means of analysing cell-free DNA (cfDNA) for detection of EGFR resistance mutations due to low success rate of repeat biopsy in NSCLC patients. However, being minimally invasive the use of liquid biopsy for early detection of EGFR mutation in treatment naïve patients is less explored.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
